Results 11 to 20 of about 19,009 (196)

Epigenetic Reactivation of TNFRSF19 Suppresses Mitophagy and Sensitizes Triple‐Negative Breast Cancer to Doxorubicin [PDF]

open access: yesAdvanced Science, EarlyView.
TNFRSF19 is an epigenetically silenced regulator of mitophagy in triple‐negative breast cancer. TNFRSF19 deficiency activates the TGFBR1–SMAD3–PINK1 axis to promote mitophagy and confer doxorubicin resistance, whereas decitabine‐mediated restoration of TNFRSF19 suppresses mitophagy and enhances doxorubicin sensitivity, revealing a targetable epigenetic–
Shiyang Liu   +7 more
wiley   +2 more sources

Development and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia [PDF]

open access: yesInternational Journal of Nanomedicine, 2017
Thomas Briot,1,2 Emilie Roger,1 Nolwenn Lautram,1 Alexis Verger,1 Anne Clavreul,3,4 Frederic Lagarce1,2 1Micro & Nanomédecines Translationelles – MINT, UNIV Angers, INSERM 1066, CNRS 6021, Université Bretagne Loire, MINT IBS-CHU,
Briot T   +5 more
doaj   +3 more sources

Nucleolin Alterations and ROS Production Associate With Sensitivity of AML Cells to Venetoclax [PDF]

open access: yesThe FASEB Journal, Volume 40, Issue 19, 15 October 2026.
Venetoclax‐induced Bcl‐2 inhibition corresponds with Mcl‐1 attenuation and decrease of Nucleolin (NCL) level and activity in sensitive cells. Simultaneously, distinct cell subpopulations with opposite mitochondrial (CellROX label, magenta) and cellular (H2DCFDA stain, green) ROS occur, and the H2DCFDA‐positive population shows markers of early ...
Kateřina Wolfová   +2 more
wiley   +2 more sources

Decitabine in the treatment of acute myeloid leukemia in elderly patients [PDF]

open access: yesCancer Management and Research, 2014
Priya Malik, Amanda F CashenWashington University School of Medicine, St Louis, MO, USAAbstract: The majority of patients with acute myeloid leukemia (AML) are elderly and have a poor prognosis despite induction therapy. Decitabine, a DNA-hypomethylating
Malik P, Cashen AF
doaj   +2 more sources

RETRACTED ARTICLE: The predictive value of BTG1 for the response of newly diagnosed acute myeloid leukemia to decitabine

open access: yesClinical Epigenetics
Background Decitabine has been widely used to treat acute myeloid leukemia (AML); however as AML is a heterogeneous disease, not all patients benefit from decitabine. This study aimed to identify markers for predicting the response to decitabine. Methods
Yi Li   +5 more
doaj   +2 more sources

Epigenetic Dysregulation of Somatostatin Receptors (SSTR) 1–5 and Therapeutic Implications in Neuroendocrine and Non‐Neuroendocrine Malignancies [PDF]

open access: yesInternational Journal of Cancer, Volume 159, Issue 11, Page 2633-2652, 1 December 2026.
ABSTRACT Somatostatin receptors (SSTR) mediate the antiproliferative, antisecretory, and proapoptotic effects of somatostatin and its synthetic analogs. Their surface expression on neuroendocrine tumor (NET) cells is required for somatostatin analog therapy and radiopharmaceutical therapy (RPT).
Neeraj Kumari   +10 more
wiley   +2 more sources

Decitabine shows anti-acute myeloid leukemia potential via regulating the miR-212-5p/CCNT2 axis

open access: yesOpen Life Sciences, 2020
Previous research has revealed the involvement of microRNA-212-5p (miR-212-5p) and cyclin T2 (CCNT2) in acute myeloid leukemia (AML). However, whether the miR-212-5p/CCNT2 axis is required for the function of decitabine in AML has not been well ...
Xing Lina   +4 more
doaj   +2 more sources

Synthetic lethality of decitabine plus ATR inhibition for TP53-mutated AML [PDF]

open access: yesBlood Adv
TP53 mutations are found in 10% to 15% of myeloid neoplasms and are associated with a dismal prognosis. Although hypomethylating agents (HMAs), such as decitabine, are active in TP53-mutated myeloid neoplasms (TP53-MN), mutation clearance is rarely ...
Baeten, Jeremy T   +13 more
core   +2 more sources

Health-related quality of life of patients with acute myeloid leukemia and myelodysplastic syndromes/neoplasms treated with decitabine: a systematic literature review [PDF]

open access: yesAnnals of Hematology
Decitabine, including its new oral formulation (decitabine-cedazuridine, DEC-C), is commonly used in AML and MDS, particularly in older or unfit patients.
Laura Cannella   +6 more
doaj   +2 more sources

Decitabine-Loaded Gold Nanocages for Photothermal Cancer Therapy via DNA Hypermethylation Reversal

open access: yes, 2021
Hypermethylation of tumor suppressor genes due to the aberrant expression of DNA methyltransferases (DNMT) is a key hallmark of cancer. However, the development of drugs targeting DNA methylation has lagged considerably.
Yangyang Du   +19 more
core   +1 more source

Home - About - Disclaimer - Privacy